Protagonist Therapeutics, Inc (PTGX) Insider Trading

Protagonist Therapeutics, Inc (PTGX)

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

Showing latest transactions and SEC Form 4 filings for PTGX.

11 results.

X Filing Date Trade Date Ticker Company Name Insider Name Title Trade Type Price Qty Owned ΔOwn Value
2026-11-17 20:29:37 2026-11-16 PTGX Protagonist Therapeutics, Inc MOLINA ARTURO MD Chief Medical Officer S - Sale $124.65 -2,718 81,397 -3% -$338,799
D 2026-10-02 16:10:06 2026-09-30 PTGX Protagonist Therapeutics, Inc Ali Asif Chief Financial Officer M - OptEx $11.86 +117,258 558,894 0% +$1,390,735
D 2026-10-02 16:10:06 2026-09-30 PTGX Protagonist Therapeutics, Inc Ali Asif Chief Financial Officer S - Sale+OE $141.78 -58,629 558,894 -8% -$8,312,294